Candel Therapeutics (CADL) Cash from Operations (2020 - 2025)

Candel Therapeutics (CADL) has 6 years of Cash from Operations data on file, last reported at 10568000.0 in Q4 2025.

• For the quarter ending Q4 2025, Cash from Operations fell 81.77% year-over-year to 10568000.0; the trailing twelve-month figure through Dec 2025 stood at 38311000.0 (down 41.77% YoY), and the FY2025 full-year result was 38311000.0, down 41.77% from the prior year.
• Cash from Operations retreated to 10568000.0 in Q4 2025, from 10236000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 4459000.0 in Q2 2021 to a low of 10819000.0 in Q1 2023.
• A 5-year average of 7660750.0 and a median of 7308500.0 in 2023 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations slumped 358.07% in 2021 and rose 25.37% in 2024, its largest moves.
• Tracing CADL's Cash from Operations over 5 years: stood at 5238000.0 in 2021, then tumbled by 31.44% to 6885000.0 in 2022, then fell by 7.8% to 7422000.0 in 2023, then climbed by 21.67% to 5814000.0 in 2024, then sank by 81.77% to 10568000.0 in 2025.
• Business Quant data shows CADL's Cash from Operations at 10568000.0 in Q4 2025, 10236000.0 in Q3 2025, and 8891000.0 in Q2 2025.